Zai Lab heads into September with a curious split: short sellers are rebuilding positions at the fastest pace in months, yet options traders have abruptly abandoned the defensiveness that defined the past two months.
The most striking move this week is in options. Zai Lab's put/call ratio has collapsed to 1.96 — nearly two standard deviations below its 20-day average of 3.74 — after spending most of August and July above 4.0. That is a dramatic rotation in sentiment. For most of the summer, options buyers were heavily skewed toward downside protection. Now they are the least defensive they have been all year, approaching the 52-week PCR low of 0.63. The shift follows the stock's near-27% single-day jump on August 6 after favourable first-in-human data for ZL-1310 in small cell lung cancer, a move that carried the stock up 42% over the subsequent five trading days. Longs chasing that rally appear to be buying calls rather than hedging.
Short sellers are reading the setup differently. Shares short have risen 16.7% over the past week, reaching 7.44 million — a roughly 20% increase over the past month. That is a meaningful acceleration, particularly against a stock that just posted one of its best single-session moves in recent memory. The borrow market remains accessible rather than distressed: availability has loosened to around 60%, well up from the near-zero readings seen in mid-August when the lending pool briefly ran dry following the data release. Cost to borrow has eased to roughly 2.3%, down sharply from the 5.5% peak recorded on August 7. The ORTEX short score has climbed to 70.3, near the top of its recent range, reinforcing the view that short positioning is elevated relative to the stock's history. The factor-based utilization rank sits in just the 6th percentile of the universe — unusually tight relative to peers even as headline availability has recovered — which suggests the lend is less comfortable than the top-line number implies.
The Street remains constructive but has been ratcheting targets lower from the peaks. Citigroup raised its price target to $45 on August 7, right after the earnings jump, maintaining a Buy. That is the most recent action and stands above the $33.14 consensus mean. JPMorgan holds an Overweight but cut its target to $32 in March, and Cantor Fitzgerald trimmed to $37 in February after starting the year at $55. The pattern across the coverage universe is one of preserved bullish ratings paired with declining conviction on valuation — analysts still see upside but are trimming their ceilings. At $25.30, the stock trades at a 31% discount to the consensus mean target, leaving plenty of notional room. The bull case rests on ZL-1310's clinical trajectory and a pipeline that spans oncology and infectious disease. Bears point to limited commercialization infrastructure, intense competition from larger pharmaceutical companies, and ongoing uncertainty around the Chinese regulatory and legal environment.
On the institutional side, the flow picture is mixed in ways worth noting. TCG Crossover Management entered the register this quarter with a fresh 6.1 million share position. FMR added roughly 500,000 shares. Against that, RA Capital trimmed by just over one million shares in mid-August — a notable reduction from a healthcare-specialist manager — and Goldman Sachs cut its disclosed position by two million shares. JPMorgan, by contrast, added roughly one million shares. The net read is one of rotation rather than wholesale exit: new money is arriving even as some established holders reduce.
The next scheduled event is Q3 earnings on November 6. The last print on August 6 delivered the stock's biggest single-day move in recent memory and reset the baseline expectations dramatically higher. With the put/call ratio at its most bullish level of the year, short interest rising at pace, and peer China-linked biopharma names broadly weaker on the week — FHTX fell 16.9% — the week ahead is less about the underlying pipeline story and more about whether the divergence between options optimism and short-seller scepticism resolves cleanly, or creates the kind of volatility that has already defined this name's 2026.
See the live data behind this article on ORTEX.
Open ZLAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
